chloroethylnorapomorphine has been researched along with preclamol in 1 studies
| Studies (chloroethylnorapomorphine) | Trials (chloroethylnorapomorphine) | Recent Studies (post-2010) (chloroethylnorapomorphine) | Studies (preclamol) | Trials (preclamol) | Recent Studies (post-2010) (preclamol) |
|---|---|---|---|---|---|
| 13 | 0 | 0 | 363 | 5 | 20 |
| Protein | Taxonomy | chloroethylnorapomorphine (IC50) | preclamol (IC50) |
|---|---|---|---|
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 2.0703 | |
| Sigma non-opioid intracellular receptor 1 | Rattus norvegicus (Norway rat) | 0.1599 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Robinson, JL; Watling, KJ; Williams, M | 1 |
1 other study(ies) available for chloroethylnorapomorphine and preclamol
| Article | Year |
|---|---|
Assessment of the chloroethyl analog of 3-PPP (N-n-propyl-3-(3-hydroxyphenyl)-piperidine), 3-PPP-C1 as an irreversible ligand for central dopaminergic recognition sites.
Topics: Animals; Aporphines; Brain; In Vitro Techniques; Ligands; Piperidines; Rats; Receptors, Dopamine | 1983 |